1
|
Abstract
Alongside imaging techniques, pulmonary function testing helps in the diagnosis of underlying disorders such as asthma and chronic obstructive pulmonary disease (COPD) or fibrosing lung disease. However, disease severity grading is also important, as well as disease follow-up under therapy. The value of spirometry as a first-line diagnostic test, whole-body plethysmography in advanced diagnostics, the measurement of transfer factor, as well as blood gas analysis are outlined. The importance of spiroergometry, echocardiography, and right-heart catheterization, particularly in the functional assessment of pulmonary vascular disorders, is described. Tests in respiratory sleep medicine, such as polysomnography, as well as tests for diagnosing chronic respiratory failure, are part of the respiratory physician's diagnostic armamentarium.
Collapse
Affiliation(s)
- M Held
- Innere Medizin, Klinikum Würzburg Mitte - Standort Missioklinik, Salvatorstr. 7, 97064, Würzburg, Deutschland.
| | - S Baron
- Innere Medizin, Klinikum Würzburg Mitte - Standort Missioklinik, Salvatorstr. 7, 97064, Würzburg, Deutschland
| | - B Jany
- Innere Medizin, Klinikum Würzburg Mitte - Standort Missioklinik, Salvatorstr. 7, 97064, Würzburg, Deutschland
| |
Collapse
|
2
|
Abstract
The vast majority of tricuspid valve regurgitations are of low degree without prognostic relevance in healthy individuals; however, morbidity and mortality increase with the degree of regurgitation, which can be secondary to either primary (structural) or secondary (functional) alterations of the valve. Due to the frequent lack of symptoms, echocardiographic examinations should be annually performed in patients with higher degree (at least moderate) tricuspid valve regurgitation, in particular in the presence of risk factors. Individual therapeutic management strategies should consider the etiology of the tricuspid valve regurgitation, the degree of regurgitation, the valve pathology and the risk-to-benefit ratio of the envisaged therapeutic procedure. Medicinal treatment options for tricuspid valve regurgitation are limited and generalized recommendations cannot be provided due to the lack of conclusive clinical trials. Symptomatic therapeutic measures encompass especially (loop) diuretics for the reduction of preload and afterload of the right ventricle. Pharmaceutical reduction of the heart rate should be avoided in patients with right heart insufficiency. While symptomatic therapeutic measures are often associated with only moderate effects, the most effective therapy of tricuspid valve regurgitation consists in the treatment of underlying illnesses, in most cases pulmonary hypertension due to pulmonary arterial hypertension (PAH), left heart disease or acute pulmonary embolism. Based on a number of published clinical studies and licensing of new drugs, treatment options for patients with PAH and heart failure with reduced ejection fraction (HFrEF) have substantially improved during the past years allowing for a differentiated, individualized management.
Collapse
Affiliation(s)
- M Lankeit
- Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum (CVK), Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland. .,Centrum für Thrombose und Hämostase (CTH), Universitätsmedizin Mainz, Mainz, Deutschland. .,Standort Berlin, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland.
| | - K Keller
- Centrum für Thrombose und Hämostase (CTH), Universitätsmedizin Mainz, Mainz, Deutschland
| | - C Tschöpe
- Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum (CVK), Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.,Standort Berlin, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland.,Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Berlin, Deutschland
| | - B Pieske
- Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum (CVK), Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.,Standort Berlin, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland.,Deutsches Herzzentrum Berlin (DHZB), Berlin, Deutschland
| |
Collapse
|
3
|
Sommer N, Richter MJ, Tello K, Grimminger F, Seeger W, Ghofrani HA, Gall H. [Update pulmonary arterial hypertension : Definitions, diagnosis, therapy]. Internist (Berl) 2017; 58:937-957. [PMID: 28819824 DOI: 10.1007/s00108-017-0301-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The term pulmonary arterial hypertension comprises a group of pulmonary vascular diseases of different etiologies that are characterized by similar precapillary vascular remodeling processes and result in exertional dyspnea and right heart insufficiency. The specific pharmacological treatment approach considers the risk of mortality and phenotypical properties and includes treatment with phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostanoids, as well as with more novel substances, such as a soluble guanylyl cyclase stimulator and an oral prostacyclin receptor agonist. The prognosis of the disease is mainly determined by the right heart insufficiency for which there is currently no specific pharmacological treatment. Lung transplantation may be offered as a last option. This review provides an overview of the current European guidelines from 2015 and the recommendations of the Cologne Consensus Conference for pulmonary hypertension from 2016.
Collapse
Affiliation(s)
- N Sommer
- Medizinische Klinik II, Universitätsklinikum Gießen und Marburg, Standort Gießen, Deutsches Zentrum für Lungenforschung (DZL), Excellence Cluster Cardiopulmonary System (ECCPS), Klinikstr. 33, 35392, Gießen, Deutschland.
| | - M J Richter
- Medizinische Klinik II, Universitätsklinikum Gießen und Marburg, Standort Gießen, Deutsches Zentrum für Lungenforschung (DZL), Excellence Cluster Cardiopulmonary System (ECCPS), Klinikstr. 33, 35392, Gießen, Deutschland
| | - K Tello
- Medizinische Klinik II, Universitätsklinikum Gießen und Marburg, Standort Gießen, Deutsches Zentrum für Lungenforschung (DZL), Excellence Cluster Cardiopulmonary System (ECCPS), Klinikstr. 33, 35392, Gießen, Deutschland
| | - F Grimminger
- Medizinische Klinik II, Universitätsklinikum Gießen und Marburg, Standort Gießen, Deutsches Zentrum für Lungenforschung (DZL), Excellence Cluster Cardiopulmonary System (ECCPS), Klinikstr. 33, 35392, Gießen, Deutschland
| | - W Seeger
- Medizinische Klinik II, Universitätsklinikum Gießen und Marburg, Standort Gießen, Deutsches Zentrum für Lungenforschung (DZL), Excellence Cluster Cardiopulmonary System (ECCPS), Klinikstr. 33, 35392, Gießen, Deutschland
- Max-Planck-Institut für Herz- und Lungenforschung, Bad Nauheim, Deutschland
| | - H A Ghofrani
- Medizinische Klinik II, Universitätsklinikum Gießen und Marburg, Standort Gießen, Deutsches Zentrum für Lungenforschung (DZL), Excellence Cluster Cardiopulmonary System (ECCPS), Klinikstr. 33, 35392, Gießen, Deutschland
- Kerckhoff-Klinik, Bad Nauheim, Deutschland
- Department of Medicine, Imperial College London, London, Großbritannien
| | - H Gall
- Medizinische Klinik II, Universitätsklinikum Gießen und Marburg, Standort Gießen, Deutsches Zentrum für Lungenforschung (DZL), Excellence Cluster Cardiopulmonary System (ECCPS), Klinikstr. 33, 35392, Gießen, Deutschland
| |
Collapse
|